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Abstract
Background: Multiple studies have demonstrated the importance of adequate catheter–tissue contact in the
creation of effective lesions during radiofrequency catheter ablation. The development of contact force (CF)-sensing
catheters has contributed significantly to improve clinical outcomes in atrial fibrillation. However, CF-sensing
technology is not used in the ablation of paroxysmal supraventricular tachycardia (PSVT). The possible reason for
this is that PSVT ablation with the conventional approach (i.e. nonirrigated, non-CF-sensing catheters) is considered
a relatively low-risk procedure with fairly high success rates (short and long term). The aim of this study is to
determine whether CF sensing can further improve the outcomes of PSVT ablation.
Methods/design: The COBRA-PATH study is a single-center, two-armed, randomized controlled trial. Patients
without structural heart disease being referred for electrophysiology study, because of PSVT and potential treatment
with radiofrequency (RF) catheter ablation, will be randomly assigned to either manual ablation with standard
nonirrigated ablation catheters or manual ablation with an open-irrigated ablation catheter equipped with CF
sensing (used in a virtual nonirrigated modus). The primary study endpoint is the difference in the number of RF
applications during the ablation of atrioventricular nodal re-entry tachycardia, and that of Wolff–Parkinson–White
syndrome and atrioventricular re-entrant tachycardia. Secondary outcome parameters include acute and long-term
procedural success rates, overall duration of RF applications, procedure/fluoroscopy durations and safety
parameters.
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Discussion: We expect to see a reduced number/duration of RF applications required to achieve effective lesion
creation, and consequently a decrease in total procedure/fluoroscopy times. Although a significant improvement in
procedural success rates (acute/long term) might not be feasible to demonstrate (given the relatively high success
rate of the standard ablation method), the possible decrease in procedure duration and the consequential
reduction of radiation exposure has important clinical implications for both operators and patients undergoing the
procedure.
Trial registration: ClinicalTrials, NCT04078685. Retrospectively registered on 2 September 2019.
Keywords: Ablation, Contact force sensing, Supraventricular tachycardia
Background
Contact force (CF) is a relatively new technology that pro-
vides real-time feedback on catheter–tissue contact during
radiofrequency (RF) ablation. There is compelling evi-
dence that CF between the tip of the catheter and the tar-
get tissue within the cardiac chamber is a key factor for
safe and effective lesion creation. Insufficient CF leads to
ineffective lesion formation whereas excessive CF may re-
sult in procedural complications. Before the development
of CF-sensing ablation catheters, operators could only rely
on surrogate indicators of tissue contact, such as tactile
feedback, intracardiac electrograms, baseline impedance,
impedance change, electrode temperature and catheter
location by fluoroscopy or electroanatomic mapping.
These measures were less accurate and did not provide in-
stant feedback on contact [1–3].
Since the introduction of CF-sensing catheter abla-
tion therapy, many studies have demonstrated the im-
portance of this novel technology in the field of atrial
fibrillation ablation, as presented in Table 1 [1, 4–19].
These investigations demonstrated that CF-sensing im-
proves the recurrence rate, significantly reducing the
total procedure, ablation times and fluoroscopy times
in comparison with conventional therapy. Moreover,
based on the findings of these clinical trials, important
CF parameters have been determined and introduced
into clinical practice guidelines for atrial fibrillation ab-
lation, such as minimum CF, target CF, minimum
force–time integral (FTI), continuity index (CI) and
lesion-size index (LSI) [7, 17, 19].
Despite compelling evidence in atrial fibrillation abla-
tion, no randomized controlled clinical trial has yet
assessed the feasibility of CF sensing in the ablation of
(paroxysmal) supraventricular tachycardia ((P)SVT). The
relatively high success rate of SVT ablations using the
conventional (non-CF-based) methodology might have
contributed to this virtual ignorance of CF sensing for
these procedures. The acute success rates of catheter ab-
lation of atrioventricular nodal re-entry tachycardia
(AVNRT) and of accessory pathway ablations (i.e.
Wolff–Parkinson–White syndrome–atrioventricular re-
entry tachycardia; WPW-AVRT) with the conventional
(non-CF-based) approach has been reported to be 96–
97% and 93% respectively, whereas the recurrence rate
of AVNRT ablation is approximately 5% and that of
WPW-AVRT ablation is around 8% [20–25]. Further-
more, in contrast to atrial fibrillation ablation, the abla-
tion target in (P)SVT usually comprises a much smaller
area of myocardial tissue (slow pathway, accessory path-
ways, cavotricuspid isthmus or an atrial focus). Another
more practical reason for the virtual ignorance of CF
sensing in (P)SVT might be the nonavailability of CF-
sensing technology in conventional nonirrigated ablation
catheters.
The aim of this randomized controlled trial (RCT) is
to demonstrate the superiority of the CF-sensing-based
approach compared to the conventional (non-CF-sens-
ing) approach in the catheter ablation of PSVTs by
assessing the improvement in the number of RF applica-
tions, and to prove the safety of the open-irrigated, CF-
sensing ablation catheters.
Methods/design
Study design
The COBRA-PATH study is a prospective, single-
center, randomized controlled trial. Patients will be
randomized to ablation using a standard (noncontact
force-sensing) catheter or ablation using a contact
force-sensing catheter (Fig. 1). The follow-up period
is 12 months from the index procedure. All operators
in the electrophysiology center of Erasmus MC have
significant experience in (P)SVT ablation (more than
200 PSVT ablations). The protocol follows the Stand-
ard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) 2013 Statement. The SPIRIT
2013 Checklist is provided in Additional file 1. Enrol-
ment, intervention and assessment according to the
time schedule of the study are presented in the
SPIRIT figure in Additional file 2.
Study population
All patients without structural heart disease being re-
ferred to participating centers for standard electro-
physiological study either because of pre-excitation
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detected on 12-lead surface ECG or because of palpita-
tions associated with documented narrow-complex
tachycardia (or clinical signs highly suggestive of the pal-
pitation being associated with PSVT: sudden onset and
termination of rapid and regular palpitations—the palpi-
tations can usually be terminated with Valsalva maneu-
ver or carotid sinus massage) will be eligible. In addition,
in order to be eligible for participating in the trial, an
electrophysiology study must identify AVNRT or WPW-
AVRT (see clarification in the following) as the under-
lying arrhythmia mechanism [26–29]. In order to be in-
cluded in the study, a subject must meet all of the
following criteria:
 Referral for electrophysiology study because of pre-
excitation on 12-lead surface ECG and/or docu-
mented (or suspected) symptomatic PSVT:
palpitations associated with narrow-complex
Table 1 Clinical studies on catheter ablations with contact force (CF)-sensing catheters in patients with atrial fibrillation
Study Year Type of study Number of patients Follow-up
(months)
Ablation CF catheter
CF Control
Martinek et al. [4] 2012 Prospective
nonrandomized study
25 25 n/a Circumferential PVI ThermoCool SmartTouch
Kuck et al. [5]
(TOCCATA)
2012 Prospective
nonrandomized study
72 n/a 12 Circumferential PVI
Right-sided SVT ablation
TactiCath
Reddy et al. [6]
(TOCCATA)
2012 Prospective
nonrandomized study
32 n/a 12 Circumferential PVI TactiCath
Neuzil et al. [7]
(EFFICAS I)
2013 Prospective
nonrandomized study
46 n/a 3 Circumferential PVI plus
remapping at 3 months
TactiCath
Casella et al. [8] 2014 Randomized
controlled trial
20 35 12 Circumferential PVI TactiCath or Contact
Therapy Cool Path
Andrade et al. [9] 2014 Prospective
nonrandomized study
25 50 13.3 Circumferential PVI ThermoCool SmartTouch
Kimura et al. [10] 2014 Randomized
controlled trial
19 19 6.7 Circumferential PVI ThermoCool SmartTouch
Marijon et al. [11] 2014 Prospective
nonrandomized study
30 30 12 Circumferential PVI ThermoCool SmartTouch
Natale et al. [12]
(SMART AF)
2014 Prospective
nonrandomized study
161 n/a 6 Circumferential PVI plus
possible linear ablations and
CFAE. CTI line if patient with AFL
ThermoCool SmartTouch
Sciarra et al. [13] 2014 Prospective
nonrandomized study
21 21 2.5 Circumferential PVI ThermoCool SmartTouch
Wakili et al. [14] 2014 Prospective
nonrandomized study
32 35 12 Circumferential PVI TactiCath
Wutzler et al. [15] 2014 Prospective
nonrandomized study
31 112 12 Circumferential PVI TactiCath
Jarman et al. [16] 2015 Retrospective case–
control study
200 400 11.4 PVIa ThermoCool SmartTouch
Ullah et al. [1] 2014 Prospective
nonrandomized study
50 50 12 PVI or WACA plus CTI plus mitral
isthmus plus roof lineb
ThermoCool SmartTouch
Kautzner et al. [17]
(EFFICAS II)
2015 Prospective
nonrandomized study
24 26 patients
from EFFICAS I
3 Circumferential PVI plus
remapping at 3 months
TactiCath
Sigmund et al. [18] 2015 Prospective case-matched
control trial
99 99 12 Circumferential PVI plus linear
ablation plus CFAEc
ThermoCool SmartTouch
Reddy et al. [19]
(TOCCA-STAR)
2015 Randomized
controlled trial
146 134 12 Circumferential PVI plus possible
linear ablations and CFAE. CTI line
if patient with AFL
TactiCath
aFor paroxysmal atrial fibrillation (AF), additional linear ablation was performed only exceptionally; nonparoxysmal AF, use of additional lesions varied by operator,
including linear lesions at the roof, mitral isthmus, posterior wall and CTI, targeting of complex fractionated electrograms, and ablation at the endocardial and
epicardial aspects of the coronary sinus
bCTI line added in patients with AFL hx; if remained in AF, linear lesions added at mitral isthmus and roof, both point-to-point and drag
cPVI only, PVI with lines, PVI with lines and CFAE, and PVI with CFAE
AFL atrial flutter, hx history n/a not applicable, PVI pulmonary vein isolation, SVT supraventricular tachycardia, CTI cavotricuspid isthmus isolation, CFAE Complex
Fractionated Atrial Electrograms, WACA wide antral circumferential ablation
Geczy et al. Trials          (2020) 21:321 Page 3 of 11
tachycardia (≥ 1 episode) documented by a 12-lead
electrogram, Holter monitoring, trans-telephonic
event recorder, telemetry strip or implanted device
(implantable loop recorder, pacemaker) within 12
months prior to referral to EPS; or frequent
symptoms of palpitation (within 12 months prior
to referral) associated with clinical signs highly
suggestive of PSVT—sudden onset and termination
of rapid (and regular) palpitations usually accom-
panied with neck pulsation and/or dizziness,
Fig. 1 Contact-Force-Sensing-Based Radiofrequency Catheter Ablation in Paroxysmal Supraventricular Tachycardias (COBRA-PATH) study flow
chart. *Symptoms highly suggestive of PSVT: sudden onset of termination of rapid (and regular) palpitations. The palpitations can usually be
terminated with the Valsalva maneuver or carotid massage. The patients have no evidence for an underlying structural heart disease. #For a
detailed explanation, see “Study population”. $For a detailed explanation, see “Preprocedural preparation and electrophysiology (EP) study”. &This
follow-up can be scheduled any time during the 12-month follow-up period, in case the patient experiences recurrent symptoms (symptom-
based follow-up). AE adverse event, AVNRT atrioventricular nodal re-entry tachycardia, CF contact force, FU follow-up, I/E inclusion/exclusion, PVST
paroxysmal supraventricular tachycardia, SAE serious adverse event, WPW-AVRT Wolff–Parkinson–White syndrome–atrioventricular
re-entrant tachycardia
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termination with Valsalva maneuver or carotid
sinus massage, and no evidence for an underlying
structural heart disease
 Identification of AVNRT or WPW-AVRT (with
manifest or concealed accessory pathway) during
standard EP study
 Verbal consent to continue with ablation therapy
after the diagnostic steps of the EPS identified
the aforementioned arrhythmia mechanisms, and
after the patient received sufficient information
about the benefits and potential risks of the
ablative treatment of the individual arrhythmia
substrate
 Informed written consent to being included in the
study
A potential subject who meets any of the following
criteria will be excluded from participating in this study:
 Evidence of structural heart disease and/or
myocardial ischemia
 Pregnancy (and lack of exclusion of potential
pregnancy)
 Age below 18 years
In this study protocol, we use the term WPW-AVRT
to describe the following disease entities:
1. Patients with evidence of a manifest accessory
pathway (i.e. pre-excitation on surface ECG and/
or findings supporting anterograde conduction
over an accessory pathway during standard EP
study) who also present with documented narrow
(or wide)-complex tachycardia, which proves to
be orthodromic (or antidromic) AVRT by the EP
study. (Note: antidromic AVRT is a quite rare
entity.)
2. Patients presenting with documented orthodromic
AVRT using a concealed bypass tract (accessory
pathway conducting only in the retrograde
direction).
3. Patients who possess a manifest accessory pathway
(pre-excitation on ECG and/or evidence for
anterograde conduction during EP study; similar to
group 1) but have never experienced palpitations
and have no prior documentation of tachycardia. In
these patients, RF ablation of the accessory pathway
will be offered for those individuals who possess a
manifest accessory pathway with an anterograde
ERP less than 240 ms, and/or for whom EP study
identifies a reproducibly inducible AVRT. These
patients can be enrolled in our study, even if no
tachycardia had been experienced or documented
in the past.
Ethics
The study protocol was approved in September 2017 by
the Medical Research Ethics Committee (2017-394) of
Erasmus Medical Center in Rotterdam, the Netherlands.
Patient inclusion began in June 2018 and is still ongoing.
Written informed consent has and will be obtained from
each participant.
Primary and secondary outcome parameters
The primary outcome of this study is the number of
radiofrequency ablations during the ablation procedures
of AVNRT and WPW-AVRT. The secondary outcome
parameters are overall duration of radiofrequency appli-
cations, acute procedural success/failure, fluoroscopy
time, total procedural duration, (serious) adverse events
and long-term procedural success. The following
additional characteristics and parameters are collected
and investigated during the study: baseline demographic
characteristics of patients, previous antiarrhythmic drug
treatment, history of cardiac arrhythmias (first onset of
PSVT, and other possible associated arrhythmias, e.g.
atrial fibrillation, atrial flutter, premature ventricular
contraction, (non)-sustained VT) and prior ablation
history.
Study groups and randomization process
Consecutive patients on the waiting/referral list for
PSVT ablations (referred to our tertiary center by other
hospitals) will be screened for eligibility by dedicated
study coordinators. When they meet the inclusion cri-
teria, the patients will be enrolled in the study (as
depicted in the flowchart for the study; see Fig. 1). After
enrolment, patients will be allocated a unique study
subject number in chronologically ascending order. Sub-
sequently, they will be randomized to two treatment
arms: the “CF-sensing” arm, ablation with a CF-sensing
ablation catheter; and the “conventional” arm, standard
ablation approach using a conventional (noncontact
force-sensing) ablation catheter. Randomization will be
performed by a computer-generated program (ALEA)
based on a block randomization protocol using a block
size factor of four. Randomization into the two treat-
ment arms will be carried out with a 1:1 randomization
ratio (50% probability for both treatment arms). The
process of randomization will follow the general
concepts of allocation concealment by incorporating
the following prerequisites into the conduct of
randomization: the EP specialists performing the abla-
tion procedures do not have knowledge on the method
of randomization utilized in the study; the EP special-
ists performing the ablation procedures do not keep a
record of the results of randomization during previous
ablation procedures; withdrawal from enrolment and
randomization after the initial screening process and
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the subsequent EP study (that was positive for AVNRT
or WPW-AVRT) must be explained thoroughly in the
official clinical report by the treating specialist; the per-
son in charge of the randomization process will not be
the treating physician and neither will he/she be in-
volved in the patient selection process; and the person
in charge of the randomization will be contacted (over
the telephone) by the treating specialist after the diag-
nostic part of the procedure has been completed. Strati-
fication for study specific factors will not be conducted.
The study will be performed in an open-label fashion:
neither the patient nor the electrophysiologist (per-
forming the procedure) will be blinded for the specific
type of procedure.
Electrophysiology procedure and catheter ablation
Preprocedural preparation and electrophysiology (EP) study
The procedures are performed under local anesthesia.
In the case of a patient on anticoagulation therapy, this
is decreased/discontinued before the procedure accord-
ing to local guidelines. Antiarrhythmic medication is
stopped 5 days before the procedure. The diagnostic EP
study is implemented according to standard protocols
for diagnosing SVTs: vascular access is created with
femoral venous puncture and multipolar diagnostic
catheters are placed in standard locations within the
cardiac chambers: the coronary sinus, the right ven-
tricle and the region of the bundle of His. Intravenous
heparin is used during the procedure for anticoagula-
tion (guided by the activated clotting time when neces-
sary). Standard pacing maneuvers (atrial/ventricular
extrastimulus testing, atrial/ventricular incremental
pacing and specific pacing maneuvers to assess
accessory pathway conduction and to induce and
analyze SVTs) are performed to confirm the diagnosis
of AVNRT or WPW-AVRT. After confirming the diag-
nosis of AVNRT/WPW-AVRT, the operator informs
the patients about the specific diagnosis and briefly de-
scribes the expected success rates and safety concerns
regarding the ablation of the particular subtype of
arrhythmia substrate. Next, in order to continue with
ablation, verbal consent is obtained from the patient
(see protocol flowchart in Fig. 1).
Mapping and ablation of the underlying arrhythmia
substrate
In the case of a left-sided ablation, the choice of access
to the left atrium/ventricle (retrograde via the femoral
artery vs. a transseptal approach) is left to the discretion
of the operator. Transseptal punctures are guided by in-
tracardiac echocardiography (ICE).
Depending on the results of the randomization, the
subsequent steps of mapping/ablation are performed
using either a conventional (nonirrigated, non-CF-
sensing) manual RF ablation catheter (conventional arm)
or the TactiCath Quartz open-irrigated contact force-
sensing catheter (CF-sensing arm). Stable catheter–tis-
sue contact (minimum of 10 s in duration) with a
minimum CF exceeding 5–10 g (and an optimal CF
within the range of 15–20 g) is targeted in the CF-
sensing group. The TactiCath catheter is used in a
virtual “nonirrigated mode” (saline flow set to ~ 1ml/
min) to achieve a similar degree of temperature control
as in the case of conventional nonirrigated catheters. In
both groups, the power (usually between 15 and 55W)
and the duration (usually between 60 and 90 s) settings
of individual RF applications will follow local laboratory
standards and will be left at the operator’s discretion.
The ablation procedures are continued until the clinical
tachycardia is no longer inducible and/or the conduction
through an accessory pathway is terminated, provided
that these clinical endpoints can be achieved with
acceptable clinical risk–benefit ratios (e.g. no signs of
imminent complete AV-block, no signs of pericardial
effusion, etc.). Thereafter, the inducibility of the clinical
tachycardia and/or conduction over an accessory path-
way is reassessed throughout a waiting time of 30 min
from the last RF application. No additional applications
are implemented until further programmed stimulation
shows evidence for recurrence of inducibility and/or re-
conduction over an accessory pathway.
Exclusion of enrolled patients from further follow-up
Patients who were originally enrolled into the study
(registered in the database and randomized to one of the
two treatment arms) are excluded from further follow-
up in the case of the following scenarios:
 The ablation catheter is not introduced into the
patient due to prior occurrence of a serious AE
(note: not during the ablation process itself), to the
withdrawal of consent or to any type of technical
difficulty with the setup.
 The ablation catheter is not introduced into the
patient or ablation is discontinued before the
achievement of acute success due to a clinical
decision to utilize a different type of catheter that is
not compatible with the study design (e.g. magnetic-
navigation guided catheters, cryoablation catheters,
etc.). Such clinical scenarios include, for example,
parahisian accessory pathways (switching to
cryoablation to prevent AV node injury), ablation of
epicardial accessory pathways from a coronary sinus
branch (magnetic navigation guided catheter for
better access) or any other situation where the
specific anatomy of the underlying arrhythmia-
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substrate involves an increased potential risk thereby
necessitating the utilization of special approaches.
However, those individuals for whom ablation was im-
plemented with a “study-compatible” ablation catheter
yet the applications were prematurely discontinued due
to the occurrence of (serious) AEs will indeed be taken
into consideration for further analyses (i.e. these patients
will not be excluded from further follow-up) in order to
be able to assess the safety aspects of CF sensing vs.
non-CF sensing during catheter ablation.
Clinical follow-up procedure
Patients are discharged home within 2 days after the
index procedure. Antiarrhythmic medication is discon-
tinued after the ablation procedure. Follow-up of study
patients is implemented as outlined in Table 2. All pa-
tients undergo physical examination, 12-lead ECG and
echocardiography before and the next day after the
procedure (note: only bedside echocardiography is per-
formed after the procedure, in order to control for peri-
cardial effusion). After discharge, patients have an
outpatient visit at 3 months and at 12 months after the
index procedure. During these outpatient visits, patients
will be assessed for recurrence of palpitations (medical
history), in addition to a physical examination and a 12-
lead ECG. Additional outpatient visits during the 12-
month follow-up period are scheduled only in the case
of recurrence of symptoms (symptom-based follow-up
appointments). In these cases, a detailed medical history
and a 12-lead ECG will be taken, and the following add-
itional examinations can also be performed (if necessary)
in order to document the clinical arrhythmia: Holter
monitoring (up to 3 weeks) and/or trans-telephonic
event recorder (CardioMemo). In the case of recurrence,
a redo electrophysiology study can be scheduled. An
event qualifies as recurrence of clinical arrhythmia if the
patient experiences identical complaints to those before
the ablation procedure, and the same type of narrow-
complex tachycardia is recorded with any of the follow-
ing: 12-lead ECG, Holter monitor or trans-telephonic
event recorder (CardioMemo). In addition, a recurrence
is also identified in case the same type of clinical
arrhythmia can be induced during a potential redo elec-
trophysiology study, that was indicated due to recurrent
palpitations. The occurrence of (serious) adverse events
will be assessed and followed-up during the procedure,
before discharge, and at 3 and 12 months post discharge
(additional follow-up appointments can also be sched-
uled if necessary). Echocardiography is done in case
follow-up of pericardial effusion/tamponade is necessary,
chest X-ray is done to follow-up possible phrenic nerve
damage and vascular ultrasound is done if vascular ac-
cess complications require it.
Adverse events and safety monitoring
Adverse events are registered and reported according to
regulations of the medical ethics committee. The occur-
rence of the following complications are considered a
major (serious) adverse event: death, acute myocardial
infarction/coronary artery damage, major bleeding,
abdominal bleeding, cardiac tamponade or pericardial
effusion requiring intervention (and/or prolonging the
duration of hospitalization), ischemic cerebral event and
other procedure-related embolic events, high-degree
AV-block requiring PM implantation, atrial esophageal
fistula, phrenic nerve palsy and vascular access compli-
cations (requiring intervention and/or prolonging the
duration of hospitalization, e.g. arteriovenous fistula, or
aneurysm). Minor adverse events are as follows: mild
pericardial effusion, minor bleeding, and minor vascular
access complications that do not require interventions
and do not prolong the duration of hospitalization; in
addition, nonsustained high-degree AV-block or sus-
tained first-degree AV-block not requiring pacemaker
implantation.
Table 2 Follow-up design of the COBRA-PATH study
Type of clinical examination Before the index
procedure
1 day after the index
procedure
3 months after the index
procedure (outpatient visit)
12 months after the index
procedure (outpatient visit)
Physical examination/historya + + + +
12-lead surface
electrocardiograma
+ + + +
Echocardiography + + (bedside echo) – –
24-h (or longer-term)
Holter monitoringa
If available – In case necessary to detect
possible recurrenceb
In case necessary to detect
possible recurrenceb
Trans-telephonic event
recorder (CardioMemo)
If available – In case necessary to detect
possible recurrenceb
In case necessary to detect
possible recurrenceb
COBRA-PATH Contact-Force-Sensing-Based Radiofrequency Catheter Ablation in Paroxysmal Supraventricular Tachycardias
aThese examinations can also be scheduled any time during the 12-month follow-up period in the case that the patient experiences recurrence of symptoms
(symptom-based follow-up appointment)
bDecision to perform these examinations will be made jointly by the treating cardiologist and the study investigators
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Since the conduct of this trial is considered low risk
for participating subjects (due to the fact that CF-
sensing catheters have already been proven by multiple
clinical studies to be safe in the ablation of other types
of cardiac arrhythmias), the ethical committee has
agreed to omit the establishment of a safety committee.
Statistical analysis
The number of radiofrequency applications during the
ablation procedures of AVNRT and WPW-AVRT (pri-
mary study endpoints), as well as other continuous pro-
cedural parameters from the group of secondary study
endpoints (such as total procedural duration, fluoros-
copy time and overall duration of RF applications), will
be expressed as mean ± SD or median (interquartile
range) depending on their distributions, and statistical
analysis of these variables will be conducted using either
the two-sample t test or the Mann–Whitney test, again
depending on the underlying distribution of the data.
The recurrence rate of PSVT at 1 year (as an indicator
of long-term success rate of the index procedure), as
well as the acute success rate and the major/minor com-
plication rates of the index procedures (secondary study
endpoints), will be presented as absolute and relative fre-
quencies. The associations between treatment and these
secondary endpoints will be analyzed with the chi-
squared test or with Fischer’s exact test, as appropriate.
Moreover, logistic regression will be performed to exam-
ine these associations and will, if needed, be adjusted for
unbalanced baseline characteristics. Freedom from PSVT
recurrence will be determined with Kaplan–Meier ana-
lysis, and differences in recurrence-free survival rates
will be evaluated with the log-rank test. A p value of
0.05 will be considered significant for all statistical deter-
minations, and all reported p-values will be based on
two-sided tests.
Sample size calculation
The sample size calculations were based on the
following:
 A retrospective analysis of AVNRT/WPW-AVRT
ablations performed in our institute within the last 6
months revealed that the mean number of
radiofrequency applications required for successful
ablations was 4.81 ± 3.21, which is in line with
previous results found in the literature [30].
 According to previous studies, the ablation efficiency
for patients with atrial fibrillation has been increased
with the use of CF-sensing technology by approxi-
mately 15–20% [1, 4–19], as revealed by the reduced
number and duration of RF applications in atrial
fibrillation ablation. We assume that in terms of
ablation efficiency, the significance of CF sensing will
be even more pronounced in the treatment (catheter
ablation) of such simple arrhythmia substrates as
that of AVNRT and WPW-AVRT, therefore
(regarding our sample calculations) a 25% reduction
in RF application number was considered realistic to
represent a clinically significant change.
Evaluation of the distribution of RF applications in our
database of AVNRT/WPW-AVRT ablations (mentioned
under the first point) revealed a positive skewness, and
therefore logarithm transformation (natural log) was
performed in order to approximate a normal distribution
of the variables. The mean and standard deviation of the
natural logs of application numbers were computed and
amounted to 1.39 ± 0.59; these values were subsequently
used in our sample size calculations.
For the sample size calculations, we used two different
calculator tools: an online sample-size calculator tool
(http://powerandsamplesize.com/Calculators/Compare-2-
Means/2-Sample-Equality) and G*power (http://www.gpo-
wer.hhu.de/en.html). In both methods, we applied the
appropriate test comparing the difference of two inde-
pendent means of two groups (calculation formulas are
presented on the calculator’s website and in G*power).
The mean application number of the group with the study
catheter was assumed to be reduced by 25% (as already
mentioned) compared to the control group (thus amount-
ing to 1.39 × 0.75 = 1.043) and the standard deviation of
this group was assumed to be identical to the control
group. The power was set to 80% and the type 1 error (α)
to 5% (two-tailed). Using these parameters, both methods/
calculators determined the same sample size of patients
(2 × 46 = 92), which would be required to show a statistical
significance in the case of a clinically significant reduction
(25%, as mentioned earlier) of RF application number.
Allowing a dropout rate of 15%, the total sample size
would become around 106. In addition, the acute
success rate of AVNRT/WPW-AVRT ablations has been
reported to be around 95% [26, 29]. Taking this into
consideration, the total number of patients required for
the purposes of this study would be 112.
Discussion
In the past decades, radiofrequency catheter ablation has
become firmly established as a first-line therapy of
paroxysmal SVT, and according to European and US
guidelines it has a Class I indication in symptomatic
cases [26, 29]. The reported short-term and long-term
success rates of the conventional approach of both
AVNRT and WPW-AVRT ablations are reasonably high
and they are also considered a safe procedure in terms
of major/minor complication rates [20, 24, 30, 31]. The
acute success rate of catheter ablation of AVNRT and
WPW-AVRT with the conventional (non-CF-based)
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approach has been reported to be 96–97% and 93%
respectively, whereas the recurrence rate of AVNRT
ablation is approximately 5% and that of WPW-AVRT
ablation is around 8% [20–25].
However, inadequate contact between the catheter tip
and the target tissue during ablation might have an im-
portant role in cases where the arrhythmia substrate is
difficult to ablate. This is especially true for such loca-
tions as the right free wall, where catheter-stability issues
can significantly hinder accessory pathway ablation [30].
We expect that adding contact force-sensing technology
to the conventional ablation approach can further im-
prove acute and long-term success rates of AVNRT/
WPW-AVRT ablations, and might also further improve
the safety profile of these procedures. In terms of basic
procedural parameters (RF application number/time,
total procedural time, fluoroscopy time), we definitely
expect an improvement compared with the conventional
technology.
Our expectations are based on the results of several
clinical trials which demonstrated that CF-sensing im-
proves clinical outcomes in patients with atrial fibrilla-
tion in comparison with conventional catheter-based
therapy [1, 4–19]. Table 1 presents an overview of these
clinical studies. These investigations have demonstrated
that CF-sensing improves the recurrence rate of atrial
fibrillation in comparison to conventional catheter-based
therapy, as well as significantly reducing the total pro-
cedure and ablation times. Moreover, CF-sensing allows
operators to spend less time assessing signal or imped-
ance drop during the ablation process. Exposure to
radiation has also been reported to diminish with CF-
sensing.
A recent meta-analysis of the controlled trials on CF-
based ablation vs. conventional approach in patients
with atrial fibrillation (presented in Table 1) has found
enhanced safety of using CF-based ablation technology
with acceptable rates of minor and major complications
and reduced rates of cardiac perforation (although this
did not reach statistical significance) [3]. This is probably
attributable to two factors: the continuous monitoring of
the catheter while manipulating the cardiac chambers,
with real-time feedback of catheter tip–tissue contact;
and avoiding ablation when the CF is suboptimal (which
would reduce the need for excessive ablations and subse-
quent related complications). We strongly believe that
through these two factors, CF sensing would have a
similar beneficial effect on the complication rate of
AVNRT/accessory pathway ablation. Therefore (based
on the aforementioned studies), as far as potential risks
associated with CF sensing are concerned, we believe
that there is no additional risks of complications ex-
pected with the use of CF sensing during AVNRT/
accessory pathway ablation. Instead, using CF sensing
should rather reduce the complication rate and enhance
the safety profile of these ablations, as well.
Despite compelling evidence in atrial fibrillation abla-
tion, no randomized controlled clinical trial has yet
assessed the feasibility of CF sensing in the ablation of
(P)SVTs. Although the TOCCATA study enrolled pa-
tients with right-sided SVTs as well, it was conducted in
a nonrandomized, uncontrolled fashion, comparing the
results of CF-sensing-based catheter ablations (per-
formed in this study with the TactiCath catheter) with
the results of conventional (non-CF-sensing-based) abla-
tion techniques reported in the literature (for right-sided
SVT) prior to the study. In addition, the focus of this
trial was the safety profile of the CF-sensing catheter,
and parameters such as the recurrence rate, total pro-
cedure/ablation time and fluoroscopy time have not
been evaluated for right-sided SVTs [5, 6].
Since catheters equipped with CF-sensing technology
already have an established role in atrial fibrillation abla-
tion, and are also demonstrated to represent a safe
methodology, we raise no potential concerns regarding
the usage of the same types of catheters in the popula-
tion of patients with PSVT. On the contrary, we strongly
believe that the aforementioned results of the CF-
sensing technology in AF ablations are also highly sug-
gestive for the potential of this technology to be benefi-
cial for PSVT patients. Since clear evidence (based on
randomized controlled clinical trials) on the superiority
of this technology in PSVT patients is currently lacking,
we believe that our study can give an answer to the
question of whether CF sensing is beneficial to use in
ablation procedures targeting less complex substrates,
like the slow-pathway of the AV node and the accessory
pathways in different anatomic locations.
Limitations
Commercially available CF-sensing catheters utilize
irrigated-tip technology as a standard feature (and cur-
rently, nonirrigated CF-sensing catheters are not being
manufactured). However, the standard catheter type
used for PSVT ablations is a nonirrigated catheter. In
order to create a comparable ablation approach, we in-
tend to use the CF-sensing catheter in a “virtual nonirri-
gated modus” (irrigation rate set at 2 ml/min), thereby
achieving similar temperature-controlled ablation char-
acteristics to those with the nonirrigated catheters. The
small amount of residual irrigation could, however, lead
to potential bias and inconsistencies as far as the homo-
geneity of the two ablation approaches are concerned,
thereby adding another possible non-negligible factor to
the equation, which can have a potential effect on out-
come and efficacy. However, based on our experience
(gained with several commercially available irrigated-tip
catheters throughout a significant number of ablations
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in our EP center), the efficacy and safety profiles of an
irrigated catheter utilized in a “nonirrigated modus” are
comparable to the characteristics of nonirrigated
ablation.
Trial status
Recruitment of participants started on 25 August 2017
and is expected to be completed on 30 June 2020. This
manuscript is based on protocol version 02 of 25 August
2017.
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